These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 11076009)

  • 1. Another case of reversibility of visual-field defect induced by vigabatrin monotherapy: is young age a favorable factor?
    Giordano L; Valseriati D; Vignoli A; Morescalchi F; Gandolfo E
    Neurol Sci; 2000 Jun; 21(3):185-6. PubMed ID: 11076009
    [No Abstract]   [Full Text] [Related]  

  • 2. Vigabatrin-induced peripheral visual field defects in patients with refractory partial epilepsy.
    Sergott RC; Bittman RM; Christen EM; Sagar SM
    Epilepsy Res; 2010 Dec; 92(2-3):170-6. PubMed ID: 20951555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electrophysiologic evaluation of a patient with peripheral visual field contraction associated with vigabatrin.
    Ruether K; Pung T; Kellner U; Schmitz B; Hartmann C; Seeliger M
    Arch Ophthalmol; 1998 Jun; 116(6):817-9. PubMed ID: 9639460
    [No Abstract]   [Full Text] [Related]  

  • 4. Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study.
    Wild JM; Chiron C; Ahn H; Baulac M; Bursztyn J; Gandolfo E; Goldberg I; Goñi FJ; Mercier F; Nordmann JP; Safran AB; Schiefer U; Perucca E
    CNS Drugs; 2009 Nov; 23(11):965-82. PubMed ID: 19845417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelling the topography of absolute defects in patients exposed to the anti-epileptic drug vigabatrin and in normal subjects using automated static suprathreshold perimetry of the entire 80° visual field.
    Besch D; Schiefer U; Eter N; Burth R; Elger CE; Spitznas M; Dietz K
    Graefes Arch Clin Exp Ophthalmol; 2011 Sep; 249(9):1333-43. PubMed ID: 21380539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nasal retinal nerve fiber layer attenuation: a biomarker for vigabatrin toxicity.
    Lawthom C; Smith PE; Wild JM
    Ophthalmology; 2009 Mar; 116(3):565-71. PubMed ID: 19168223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visual field defect associated with vigabatrin. Method of estimating prevalence was inappropriate.
    Manuchehri K
    BMJ; 2000 May; 320(7246):1403-4; author reply 1404. PubMed ID: 10858055
    [No Abstract]   [Full Text] [Related]  

  • 8. [Severe constriction of the visual field associated with vigabatrin discovered by thorough examination of a 17-year old girl].
    Roubergue A; Pelosse B; Doummar D; Beauvais P; Montchilova M; Gonthier B; Billette de Villemeur T
    Arch Pediatr; 1999 Aug; 6(8):901-2. PubMed ID: 10472407
    [No Abstract]   [Full Text] [Related]  

  • 9. [Constriction of the visual field by vigabatrin].
    Asensio Sánchez VM
    An Med Interna; 2002 Dec; 19(12):655-6. PubMed ID: 12593042
    [No Abstract]   [Full Text] [Related]  

  • 10. Visual field defect associated with vigabatrin: observational cohort study.
    Wilton LV; Stephens MD; Mann RD
    BMJ; 1999 Oct; 319(7218):1165-6. PubMed ID: 10541505
    [No Abstract]   [Full Text] [Related]  

  • 11. [The function of eye and vision system in children and youth treated with vigabatrin--our own experiences].
    Pojda-Wilczek D; Emich-Widera E; Herba E; Pojda SM; Marszał E
    Klin Oczna; 2005; 107(10-12):654-7. PubMed ID: 16619812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Vigabatrin and visual fields defects].
    Jensen K
    Ugeskr Laeger; 2001 Jan; 163(2):184. PubMed ID: 11379251
    [No Abstract]   [Full Text] [Related]  

  • 13. Visual field defect associated with vigabatrin. Means of selecting patients was misleading.
    Midelfart A
    BMJ; 2000 May; 320(7246):1404. PubMed ID: 10858056
    [No Abstract]   [Full Text] [Related]  

  • 14. Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review.
    Maguire MJ; Hemming K; Wild JM; Hutton JL; Marson AG
    Epilepsia; 2010 Dec; 51(12):2423-31. PubMed ID: 21070215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Visual field defect associated with vigabatrin. Many more patients may be affected than were found in study.
    Comaish IF; Gorman C; Galloway NR
    BMJ; 2000 May; 320(7246):1403; author reply 1404. PubMed ID: 10858054
    [No Abstract]   [Full Text] [Related]  

  • 16. Are vigabatrin-associated visual field constrictions asymptomatic?
    Schmidt T; Rüther K; Schmitz B
    J Neurol; 2004 Jul; 251(7):887-8. PubMed ID: 15258797
    [No Abstract]   [Full Text] [Related]  

  • 17. Reversibility of vigabratin-induced visual-field defect.
    Versino M; Veggiotti P
    Lancet; 1999 Aug; 354(9177):486. PubMed ID: 10465180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retinal nerve fibre layer attenuation: clinical indicator for vigabatrin toxicity.
    Moseng L; Sæter M; Mørch-Johnsen GH; Hoff JM; Gajda A; Brodtkorb E; Midelfart A
    Acta Ophthalmol; 2011 Aug; 89(5):452-8. PubMed ID: 21251242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epilepsy: Vigabatrin treatment and visual field loss.
    Chiron C; Dulac O
    Nat Rev Neurol; 2011 Apr; 7(4):189-90. PubMed ID: 21364521
    [No Abstract]   [Full Text] [Related]  

  • 20. Vigabatrin-associated visual field loss.
    Fecarotta C; Sergott RC
    Int Ophthalmol Clin; 2012; 52(3):87-94, xii. PubMed ID: 22668542
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.